Document is current
Any future updates will be listed below
-
Authors
Berretta, Sarah A.
Abaya, Nicole
Parrish, Emma
McBride, Lauren E.
Moore, Raeanne C.
Ackerman, Robert
Harvey, Philip D.
Pinkham, Amy E.
Depp, Colin A.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (5R61MH129379-02, 5R61MH129379-02, 5R61MH129379-02, 5R61MH129379-02, 5R61MH129379-02, 5R61MH129379-02, 5R61MH129379-02, 5R61MH129379-02, 5R61MH129379-02)
- License Information
-
More Information
Article History
Received: 17 October 2024
Revised: 12 December 2024
Accepted: 23 December 2024
First Online: 14 February 2025
Competing interests
: Dr. Harvey has received consulting fees or travel reimbursements from Alkermes, Bio Excel, Boehringer Ingelheim, Karuna Pharma, Merck Pharma, Minerva Pharma, and Sunovion (DSP) Pharma in the past year. Dr. Harvey receives royalties from the Brief Assessment of Cognition in Schizophrenia (Owned by WCG Verasci, Inc. and contained in the MCCB). Dr. Harvey is chief scientific officer of i-Function, Inc. and Scientific Consultant to EMA Wellness, Inc. Dr. Depp has received consulting fees from WCG Clinical and Boehringer Ingelheim. Dr. Moore is a co-founder of KeyWise AI, Inc. and NeuroUX Inc. No other authors have conflicts of interest to report.
